Even the least sceptical agree that a large proportion of research upon therapeutic substances turns out to be research about placebos. Recent estimates based on American observations suggest that 30 per cent. of currently advertised remedies are dropped by their makers each year. Not all these are dropped because experience shows that they have no direct pharmacological action; some are no doubt withdrawn because they are toxic. Further, not all remedies that are well-known to be useful are extensively advertised, and so the estimate is therefore too high as a measure of the proportion of substances in present use that are in fact placebos. But perhaps 15 per cent. would be a conservative estimate of the number of inactive substances discovered to be so and dropped each year: even so, about 39 per cent. of substances in current use would be found to be inactive within 3 years, and half the entire manufacturers' lists would be turned over for this reason alone within 5 years. On the other hand, new brands of drugs with certain kinds of central action (the so-called "tranquillizers") are being introduced in such volume that they double in number about every 2 years. It is therefore necessary to investigate the placebo effect deliberately, efficiently, and experimentally, since it is clearly to this factor that so many new substances owe their initially impressive but transient effect.
Pepper (1945) Felsinger, and Beecher (1954) were the first to point out that the "personalities" of clinical reactors and non-reactors to placebos given for pain following major surgery differed in ways that could be measured. Interviews by psychiatrists, ratings by hospital staff, and scores on Rorschach tests agreed in suggesting strongly that the reactors were "not whiners or nuisances, not typically male or female, young or old and (they) had the same average intelligence as the non-reactors . . . all considered the hospital care 'wonderful' whereas (few) non-reactors felt this way. The reactors tended to ask less frequently for medications and to be more cooperative .. . The reactors also tended to have more 'somatic' symptoms ... during periods of stress . . . There was a definitely greater use of cathartics . . . they tended to be more emotionally expressive and . . . to speak freely, most frequently of themselves and their problems . . . they were more frequently active church-goers . . . and had less formal education". They also "liked everyone". It is perhaps not surprising to us, after learning that reactors are not whiners, that hospital staff who attempted to guess which patients were reactors and which were not guessed wrong more frequently than they guessed right.
These were American surgical patients, aged between 20 and 79. In the laboratories of this medical school the reactions to dummies of healthy British medical students aged 18 to 30 have been experimentally investigated for some time.
Instead of Rorschach and psychiatric interviews, we used conventional pencil and paper personality tests, and background information collected during routine investigations. Briefly, it turned out that the experimental reactors (that is to say, those subjects who thought that they had taken an active drug when in fact they had received only a dummy) were more aware of social pressures, more extroverted, less "dominant", and more neurotic than the non-reactors. They rated their performance less highly in classwork and were in general less self-confident. They had not, it appeared, more previous experience with drugs than non-reactors, but they did show a greater expectancy that any drug would have more effect upon them than did the non-reactors. They also had higher resting pulse rates than the latter, and their pulse rates were more labile under stress.
However, the basic question is whether there is. or is not such a person as a consistent placebo reactor and such a person as a consistent nonreactor. Wolf (1959) failed to show in his own experimental studies that the occurrence of reactions in a very small group of experimental subjects followed anything other than a chance distribution, and for his group this was no doubt true. However, to this field perhaps more than to any other applies. Delisle Burns's dictum that people working on the central nervous system should declare their bias in advance (Burns, 1958) : so, perhaps because we expected to find a greater degree of patterning in the responses than chance would lead one to predict, we indeed found this to be so (Joyce, 1959 Uhlenhuth, Canter, Neustadt, and Payson (1959) that the true differences between meprobamate and phenobarbitone on the one hand and a placebo on the other, in a clinical trial with anxious out-patients, only emerge if the physician conveys his expectation that some remedy used in a double-blind trial will be useful to the patient. If he is too detached, and manifests no such optimistic expectation at all, no differences are found. Knowles and Lucas (1960) , in one of the very few laboratory investigations of the placebo response so far published, draw attention to another factor that profoundly modifies the situation: this is the presence or absence of other subjects when the treatment is given and the responses to it recorded. Their reactors to dummies had a higher "neuroticism" score on the Maudsley Personality Inventory than did their non-reactors if the dummy was given to groups of three subjects at a time; but those who were reactors showed no differences in "neuroticism" scores when the substance was given to them individually. On the other hand, individual treatment gave reactors with higher "extroversion" scores; whereas when treated in groups of three, reactors and non-reactors did not differ on this measure.
One might speculate at length about the reasons for these findings. Their practical importance, however, is unmistakable, because drugs and placebos are given in the hospital ward under something that approximates to group conditions, and in out-patient or private practice for consumption at home under something like individual conditions. Here the circumstances are, of course, "contaminated", because other patients or friends or members of the family are receiving different treatments or none at all; and Nowlis and Nowlis (1956), in some suggestive work that they have unfortunately discontinued and published little about, have shown us that the presence in a group treated with one active substance of a member treated with another produces some very unexpected results in all of them. Starkweather (1959) and Goldstein, Searle, and Schimke (1960) find similar effects, although different in direction.
In a long, so far unpublished paper, A. J. Young of Leeds has considered other relationships between personality factors and reaction tendencies in arthritic out-patients. His groups are small and his measures many, but his results suggest that positive reactors ("improved patients" in his terminology) are introverted and neurotic and that negative reactors ("adversely affected patients") are dominant. He also finds that both kinds of reactor are likely "to be suffering from an arthritis precipitated by an emotional stress". He proposes that somatic changes, whether related to a disease process or to relatively acute or short-lasting chronic events such as drug administration, are more likely to occur in such people because of psychological rather than physiological events. This is an artificial dichotomy, and the factor, he believes, is not a simple one; but it agrees with our own view that reactors are more sensitive to what we may call "information" of all kinds-whether this arises from their environment, from others in their context (such as doctors and other patients or subjects), or their own viscera. We are at present trying out some ideas about the ways in which reactors and non-reactors handle sense-data of different kinds.
We scarcely know more as yet than that under some specified conditions the placebo will "work" reliably, but this is a valuable start. It seems that improvement in the definition of these conditions, for which both laboratory and clinical experiment will be necessary, is extremely likely to give valuable practical results.
Summary
Little is known of the pharmacology of the "placebo", partly because there are so many different kinds of placebo which vary in their actions, and partly because there are so many different kinds of individuals to react to them. Placebo reactors can be divided into "positive reactors", who produce reactions in the desired or therapeutic direction, "negative reactors", who react in a way opposed to that desired, and "non-reactors", who show no effect at all. Reactors are more aware of social pressures, more extroverted, less dominant, and more neurotic than non-reactors. They are also less self-confident and show a greater expectancy that the "drug" will be effective. Modes of presentation of active drugs and placebos in clinical trials are also important. The effect of the administration of a drug in hospital may differ from that of a drug administered in general practice because the former is given to a patient who is one of a group, and the latter to an individual acting alone. be interesting to relate the response of positive reactors to "hypnotizability"? There must be some common factor of suggestibility and this would be a good start.
DR. ADAMS: There is no positive correlation between the number of people reacting positively and their suggestibility. Whether that is the same thing I do not know.
DR. V. WRIGHT (Leeds): This is a subject in which Prof. Hartfall has been interested for some time. A study was carried out with the intra-articular therapy, and it was observed that 36 per cent. of our patients claimed improvement; arising from that work, we began further studies. Dr. Young and Dr. Morrison interviewed all patients, taking a full psychological history, and then gave a course of placebo tablets. Some patients claimed improvement from injections rather than from placebo tablets-one would anticipate this. It was found also that those at the Maudsley who had improved were more neurotic and introverted. The most interesting point was that when we came to assess the correlation between side-effects and placebo response, patients who were consistent non-reactors failed to show side-effects at any time, and this was statistically significant at the 1 per cent. level of probability. It seems possible that, if one is anxious to know in a trial which patients will show side-effects, one may give a week's course of placebo tablets, and observe those who develop sideeffects. This would show who were reactors in the group and would enable a highly selected group on which to work to be chosen.
Experiences avec des substances de contr6le RESUME La pharmacologic du "placebo" (substance inerte ou substance-temoin) est peu connue. Les sujets recevant des "placebos" peuvent etre divisis selon leur reaction en "positifs", "negatifs" et "non-reagissants". Les 
